RxDoctor Payments Data

Frederick Wood, MD

Cardiovascular Disease · Murrieta, CANPI 1164479473

Payments from drug & device makers

$18,289in general payments, 2019–2025

Across 1,010 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • Johnson & Johnson$2K
  • Pfizer$2K
  • Amarin Pharma, Inc.$1K
  • plus $8K from 39 others

What the payments were for

  • Food & beverage$18,14699%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,289 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$390,613
Medicare patients
495
Services billed
4,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$154,306
XareltoRivaroxaban65$75,433
JardianceEmpagliflozin38$50,944
EntrestoSacubitril/Valsartan30$48,274
VascepaIcosapent Ethyl47$43,040
FarxigaDapagliflozin Propanediol22$31,485
Repatha SureclickEvolocumab18$28,631
OzempicSemaglutide17$25,271
BrilintaTicagrelor19$22,094
MultaqDronedarone Hcl12$18,036
EdarbiAzilsartan Medoxomil24$17,015
NexletolBempedoic Acid17$15,985
RybelsusSemaglutide14$15,033
Nebivolol Hcl116$7,417
Icosapent Ethyl12$4,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,510$154,306130 claims
Johnson & JohnsonXarelto$1,622$75,43365 claims
AstraZenecaFarxiga, Brilinta$1,784$53,57941 claims
Boehringer IngelheimJardiance$1,630$50,94438 claims
NovartisEntresto$2,377$48,27430 claims
Novo NordiskOzempic, Rybelsus$553$40,30431 claims
Sanofi-aventis U.S. LLCMultaq$1,099$18,03612 claims
Arbor Pharmaceuticals, Inc.Edarbi$244$17,01524 claims
Esperion Therapeutics, Inc.Nexletol$597$15,98517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →